Larimar Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+3.27%
vs ±18.6% implied · ×0.18
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Larimar Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Larimar Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Deerfield | $108.6M | 36.85% | 0.00% |
| Blue Owl Capital | $27.9M | 9.48% | +28.70% |
| BlackRockindex-like | $17.3M | 5.88% | +51.33% |
| Defilade | $11.2M | 3.80% | new |
| Driehaus | $9.6M | 3.27% | +7.80% |
| Manager | Value | % base | |
|---|---|---|---|
| Deerfield | $108.6M | 36.85% | 0.00% |
| Blue Owl Capital | $27.9M | 9.48% | +28.70% |
| BlackRockindex-like | $17.3M | 5.88% | +51.33% |
| Defilade | $11.2M | 3.80% | new |
| Driehaus | $9.6M | 3.27% | +7.80% |
Bull3
Bear1
Larimar Therapeutics, Inc.
2.54
+0.17 · +7.17%
post 2.59 +1.97%
Expected move
Inputs8Q avg ±8.2%·×4.37·rich
straddle ±35.9%
spot 2.43exp Nov 20ATM strike 2.5ATM straddle 1.02IV 236%